When it comes to high-yield dividend growth legends, there are few lower risk names than Johnson & Johnson.

JNJ's massive scale and diversification means that its 55-year streak of dividend growth is likely to continue for decades to come.

That's especially true, given the company's strong growth opportunities in the developing world, cardiac medicine, and oncology.

However, the strong stock performance over the past year means that JNJ is now ridiculously overpriced.

READ FULL ARTICLE HERE